Economic evaluations of human papillomavirus vaccines (Q37763114)

22 August 2017

title

Economic evaluations of human papillomavirus vaccines (English)

1 reference

22 August 2017

1 reference

human papillomavirus vaccine

29 September 2024

1

Ruanne V Barnabas

1 reference

22 August 2017

Shalini L Kulasingam

2

1 reference

22 August 2017

publication date

1 June 2007

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

22 August 2017

published in

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

251-267

1 reference

Global cancer statistics, 2002

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Cancer burden in the year 2000. The global picture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Chapter 2: The burden of HPV-related cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Chapter 5: Updating the natural history of HPV and anogenital cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

The 2001 Bethesda System: terminology for reporting results of cervical cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Chapter 13: Current findings from prophylactic HPV vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

An introduction to mathematical models in sexually transmitted disease epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Evaluating human papillomavirus vaccination programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Model for assessing human papillomavirus vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Vaccination against multiple HPV types

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Prospective follow-up of cervical HPV infections: life table analysis of histopathological, cytological and colposcopic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Clearance of HPV infection in middle aged men and women after 9 years' follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

The global health burden of infection-associated cancers in the year 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Immunization with a pentameric L1 fusion protein protects against papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.7.3.251

21 January 2018

Identifiers

DOI

10.1586/14737167.7.3.251

1 reference

22 August 2017

1 reference